Nabeela Ahmed Memon regulatory affairs pharmacist in the Kingdom of Bahrain with nearly a decade of progressive experience at the National Health Regulatory Authority (NHRA).

Currently serves as Head of Registration & Pricing and holds the additional responsibility of Chief of Pharmacy & Pharmaceutical Products Regulation department, leading national oversight of medicine registration, pricing, and regulatory compliance.

Leads national operations for pharmaceutical product registration and pricing, overseeing innovative, generic, and non-registered medicine portfolios in alignment with GCC and international standards.

Spearheaded the digital transformation of medicine registration through full implementation of the “Adweya” system, reducing review timelines by 35% and enhancing regulatory efficiency.

Deputy Chairperson of the Pharmaceutical Products Licensing Committee and represents Bahrain in regional GCC regulatory harmonization and GMP initiatives.

Recipient of the prestigious Prince Salman bin Hamad Medical Merit Award in recognition of her leadership and outstanding contribution during Bahrain’s national COVID-19 response.

Samar Abdalhalim graduated with a bachelor’s degree in Pharmaceutical Sciences in 2007.

With over 18 years of dedicated experience in the pharmaceutical and personal healthcare industry, Samar Abdalhalim has had the privilege of making significant contributions to the regulatory field. She has been at the forefront of shaping the regulatory landscape and ensuring compliance within the P&G Health organization.

Samar Abdalhalim has held various positions at leading companies such as Johnson & Johnson and, Procter & Gamble , where she honed her expertise in regulatory & medical affairs , research & development , product research and strategic planning.

Dr. Mona Al Moussli is the Co-Founder and Managing Director of PRA Consultancy, with over 20 years of expertise in pharmaceutical and medical device regulatory affairs. She has led key initiatives like the GCC Regulatory Affairs Summit and the AfriSummit and developed the GCC Regulatory Affairs Course. Dr. Al Moussli also serves on several advisory boards, contributing to healthcare advancement and regulatory excellence in the region.

Dr. Sboul is the Group Lead of Pharmaceutical Industry as part of the National Team responsible for developing Jordan’s Economic Modernization Vision 2023-2033, she is also a member of the Board of Jordan Food and Drug Administration JFDA, a member of Hashemite University Board of Trustees, the Vice Chair of the Steering Committee for the Jordan Pharmaceutical Center of Excellence, member of the Advisory Council of Pharmacy School at Jordan University of Science & Technology.

Dr. Sboul has also served as a Member of several Boards, including the Higher Education Council and The Higher Committee for Drugs & Pharmacy, the Scientific Research Support Fund, the Fund for Employment, Technical, Vocational Education & Training (E-TVET Fund), the University of Science & Technology Council, the Council of Pharmacy School at Jordan University.

At international level, Dr. Sboul was the Chair of the International Generic & Biosimilar Medicines Association IGBA in 2020. She was also a member of the USP Council of Convention, the Chair of the USP Convention Membership Committee & the Chair of USP MENA Regional Chapter. In her current and previous roles, Ms. Sboul is actively engaged in enhancing the regulatory landscape for pharmaceuticals to improve access to quality, safe & effective medicines and support local pharmaceutical industry.

Dr. Sboul received her MBA from Jordan University in 2000 and received her B.A in Pharmacy from Yarmouk University. She was the first Association Executive from Jordan to receive the Certified Association Executive Certificate from the American Society for Association Executives in 2005.

Ramez Sawiris serves as the R&D Head for Haleon Middle East and Africa and is the Vice Chair of MENAP-SMI (Middle East, North Africa, Pakistan Self Medication Industry), where he has played an important role in leading discussions on self-care in the region. With over 20 years of experience in the pharma and consumer healthcare industries, Ramez oversees the research and development activities across the MEA region, ensuring the delivery of innovative and high-quality products that align with consumer needs and local regulatory standards.

Ramez holds a robust background in regulatory affairs, regulatory strategy development, pricing, and external engagement. Through his leadership, Ramez has built and maintained strategic partnerships with key stakeholders including government agencies, industry associations, and healthcare professionals, reinforcing Haleon’s commitment to deliver better everyday health with Humanity across MEA. Ramez also holds an MBA in Management from the University of Bradford, UK and a Bachelor of Pharmacy and pharmaceutical science from Cairo University.

Mr. Marwan Zeidan is leading EVOTEQ’s business development and client relationships, responsible to drive growth while maintaining client satisfaction.

He has over 25 years of rich experience that has encompassed various disciplines in business development, sales and delivery across complex IT/OT digital solutions, public sector offerings, and smart buildings/cities. Prior to joining EVOTEQ, he was leading TASMU, Qatar’s national smart city platform within the Ministry of Communications and Information Technology.

He held various roles in Schneider Electric, supporting customers in their digital transformation, leveraging the best in Operational Technology solutions with advanced Information Technology. He was also an Associate Partner with IBM leading Watson IoT Services for MEA, and a Senior Manager with Cisco Systems leading consulting and solution selling for Smart Cities in Europe and MEA. He also held positions with consulting companies that include Accenture and Deloitte & Touche.

Mr. Marwan graduated from the American University of Beirut with a degree in Computer and Communications Engineering.

Dr. Rawya is a clinical pharmacist with broad Medical and Pharmaceutical knowledge, experience in various aspects of the Pharmaceutical Industry especially Medical Affairs, Regulatory Affairs and Pharmacovigilance, as well as knowledge and experience in the research field. She has a M.Sc. Clinical Pharmacy (with Distinction) – Queen’s University, UK.
Dr. Rawya began her career at Hikma Pharmaceuticals, Jordan since 1998 till 1999, and she is currently the Regulatory Affairs & Medical Affairs Director at Gulf Pharmaceutical Industries (Julphar), Ras Al Khaimah, United Arab Emirates since 2020 – to the present date.
In her role in Regulatory affairs, she displays and actions leadership in all aspects of Regulatory Affairs for company product portfolio of generics and novel products, including product development and submissions.
She is also an expert in defining the strategic regulatory direction for pipeline development and global launch excellence for a significant dedicated R&D budget. In addition, Dr. Rawya is knowledgeable of partnering with R&D and Global Strategic Marketing leaders as well another functional leader to develop and implement strategy for pipeline development and global launch excellence.

With over 23 years of experience in the biopharmaceutical industry, Varma Bhupathiraju is a recognized leader in global regulatory affairs, specializing in the development and approval of biologics. He has played a pivotal role in securing approvals for multiple biological products, including biosimilars and vaccines, across key global markets such as LATAM, MENA, CIS, AFRICA, and APAC. Notably, he pioneered the first-ever US FDA approval for a vaccine candidate from an Indian manufacturer.

Varma has successfully obtained regulatory approvals in over 100 countries and secured GMP accreditations from leading regulatory agencies, including ANVISA-Brazil, COFEPRIS-Mexico, ANMAT-Argentina, ISP-Chile, SAHPRA-South Africa, NPRA-Malaysia, DAV-Vietnam, EDA-Egypt, NAFDAC-Nigeria, TMDA-Tanzania, NDA-Uganda, MCAZ-Zimbabwe, WHO, ensuring alignment to facilitate market access. Additionally, he has been instrumental in streamlining regulatory approval processes in India.

Currently, Varma leads the regulatory team for Emerging Markets and India, driving the company’s mission to expand patient access to affordable biologics.

Mr. Mete Karaca serves as an Executive Board Member at Tiga Healthcare Technologies, where he spearheads Business Development initiatives, driving the company’s growth and strategic partnerships in the healthcare IT landscape. With a robust technical foundation stemming from a bachelor’s degree in Electrical and Electronics Engineering, Mr. Karaca combines analytical precision with innovative problem-solving skills, enabling him to address complex challenges in the ever-evolving healthcare technology sector.

To complement his technical expertise, Mr. Karaca pursued a master’s degree in Engineering Management, where he cultivated advanced project management capabilities and honed his leadership acumen. This multidisciplinary background has positioned him as a dynamic leader who seamlessly integrates technical knowledge with strategic vision, delivering transformative results across a wide range of projects.

Over nearly two decades, Mr. Karaca has led and delivered numerous health IT projects across the globe, with notable experience, especially in national-scale healthcare information systems. His expertise spans key domains such as Healthcare Interoperability, Health Information Exchange, Personal Health Record (PHR), Central e-Prescription, Pharmaceutical Track and Trace System and Hospital Information System (HIS), solidifying his reputation as a trusted leader in transforming healthcare infrastructure on a national level. His work in the GCC region has been particularly impactful, showcasing his ability to manage multi-stakeholder collaborations with public healthcare authorities, regulators and leading organizations. This extensive experience underscores his versatility and expertise in complex, high-impact projects with precision and efficiency.

Mr. Karaca’s profound understanding of the intersection between healthcare and technology has enabled him to advance innovation within the industry. His leadership continues to shape projects that merge cutting-edge technologies with patient-centric solutions, setting new benchmarks for efficiency and effectiveness in healthcare delivery. As a forward-thinking leader, Mr. Karaca remains dedicated to driving progress and fostering meaningful change in healthcare IT worldwide.